Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KROS - Keros Therapeutics Inc


IEX Last Trade
45.45
0.140   0.308%

Share volume: 191,272
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$45.31
0.14
0.31%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-0.35%
1 Month
-11.72%
3 Months
-2.07%
6 Months
-33.38%
1 Year
27.46%
2 Year
28.18%
Key data
Stock price
$45.45
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$27.02 - $73.00
52 WEEK CHANGE
$0.25
MARKET CAP 
1.702 B
YIELD 
N/A
SHARES OUTSTANDING 
37.522 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
BETA 
1.07
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$232,172
AVERAGE 30 VOLUME 
$272,471
Company detail
CEO:
Region: US
Website: kerostx.com
Employees: 104
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

keros therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. the company's lead protein therapeutic product candidate is ker-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or mds, and in patients with myelofibrosis. it is also developing small molecule product candidate ker-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or fop, and is currently in a phase 1 clinical trial; and ker-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or pah. the company was founded i

Recent news